Rayner Surgical Inc v. Amneal Pharmaceuticals Of New York LLC

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Rayner Surgical Inc. (Delaware) and Rayner Intraocular Lenses Ltd. (England)
  • Defendant: Amneal Pharmaceuticals of New York, LLC (Delaware); Amneal Pharmaceuticals LLC (Delaware); Amneal Pharmaceuticals, Inc. (Delaware); and Amneal EU, Limited (Ireland)
  • Plaintiff's Counsel: Saul Ewing LLP
• Case Identification: 3:26-cv-03629, D.N.J., 04/06/2026
• Venue Allegations: Venue is alleged to be proper in the District of New Jersey because the U.S.-based Amneal defendants are alleged to have a regular and established place of business in the state and to have committed acts of infringement there. Venue over the foreign defendant, Amneal EU, Limited, is based on its status as a foreign corporation.
• Core Dispute: Plaintiff alleges that Defendant's submission of an Abbreviated New Drug Application (ANDA) to the FDA for a generic version of Plaintiff's OMIDRIA® product constitutes an act of infringement of three patents related to stable, injectable ophthalmic solutions.
• Technical Context: The technology concerns preservative-free and antioxidant-free pharmaceutical formulations containing phenylephrine and ketorolac, designed for injection into irrigation solutions used during ophthalmic surgery to maintain pupil dilation and reduce postoperative pain.
• Key Procedural History: This infringement action was brought under the Hatch-Waxman Act, triggered by Defendant's filing of ANDA No. 220463 with a Paragraph IV certification, signaling its intent to market a generic drug prior to the expiration of the patents-in-suit. The complaint notes that a related matter involving the same plaintiffs and patents is pending in the same district against a different defendant, Somerset Therapeutics, LLC.

Case Timeline

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 9,066,856 - Stable Preservative-Free Mydriatic and Anti-Inflammatory Solutions for Injection

The Invention Explained

• Problem Addressed: The patent's background describes challenges in ophthalmic surgery where maintaining pupil dilation (mydriasis) is critical, as constriction (miosis) increases procedural risks Compl. ¶29 '856 Patent, col. 1:50-58 Standard mydriatic agents like epinephrine, when added to irrigation solutions, often contain preservatives or antioxidants (e.g., sodium metabisulfite) that can be toxic to sensitive ocular tissues, potentially causing complications like Toxic Anterior Segment Syndrome (TASS) '856 Patent, col. 1:61-col. 2:11 There is also a need to reduce postoperative pain associated with such surgeries '856 Patent, col. 2:24-30
• The Patented Solution: The invention is a sterile liquid pharmaceutical formulation that is stable without the need for preservatives or antioxidants '856 Patent, abstract It combines a mydriatic agent, phenylephrine, to maintain pupil dilation with an anti-inflammatory agent, ketorolac, to manage pain and inflammation, all within a buffered aqueous solution designed for injection into a larger volume of intraocular irrigation fluid '856 Patent, col. 3:46-52 This combination allows for simultaneous drug delivery during the surgical procedure itself.
• Technical Importance: The formulation provides a method to safely maintain pupil dilation and control pain during surgery by eliminating the need for potentially toxic preservatives and antioxidants commonly found in other injectable ophthalmic products '856 Patent, col. 3:4-14

Key Claims at a Glance

• The complaint asserts infringement of "one or more claims" of the '856 Patent, with a specific focus on independent claim 1 Compl. ¶47 Compl. ¶49
• Independent Claim 1:
  • A sterile liquid pharmaceutical formulation consisting essentially of phenylephrine, ketorolac and a buffer system in an aqueous carrier,
  • wherein the formulation is stable for at least six months when stored at a temperature of from 5+/-3° C. to 25 +/-2° C.
• The complaint's allegation of infringement of "one or more claims" preserves the right to assert other independent or dependent claims.

U.S. Patent No. 9,486,406 - Stable Preservative-Free Mydriatic and Anti-Inflammatory Solutions for Injection

The Invention Explained

• Problem Addressed: As a continuation of the application leading to the '856 Patent, this patent addresses the same technical problem: the need for a safe and effective way to maintain pupil dilation and reduce pain during ophthalmic surgery without introducing potentially toxic preservatives or antioxidants into the eye '406 Patent, col. 1:51-col. 2:11
• The Patented Solution: The '406 Patent describes a sterile liquid formulation that is explicitly "without the inclusion of preservatives and antioxidants" '406 Patent, abstract It combines phenylephrine and ketorolac in a buffered aqueous carrier, achieving stability sufficient for a commercial pharmaceutical product intended for injection into an intraocular irrigation solution '406 Patent, col. 4:1-13
• Technical Importance: This invention provides a stable, dual-action injectable for ophthalmic surgery that avoids the use of additives linked to ocular toxicity.

Key Claims at a Glance

• The complaint alleges infringement of "one or more claims" of the '406 Patent and specifically recites independent claim 2 Compl. ¶69 Compl. ¶71
• Independent Claim 2:
  • A liquid pharmaceutical formulation comprising phenylephrine, ketorolac and a buffer system in an aqueous carrier,
  • wherein the formulation is stable without the inclusion of preservatives and antioxidants for at least six months when stored at a temperature of from 5+/-3°C. to 25+/-2° C.
• The complaint's broad allegation preserves the right to assert other claims.

U.S. Patent No. 9,855,246 - Stable Preservative-Free Mydriatic and Anti-Inflammatory Solutions for Injection

Technology Synopsis

Continuing the work of the prior patents, the '246 Patent describes a stable, injectable solution of phenylephrine and ketorolac that is free of preservatives, antioxidants, and solubilizing agents '246 Patent, abstract This patent adds a further element to enhance stability: the formulation is packaged in a single-use container with a nitrogen gas overlay to displace oxygen '246 Patent, abstract '246 Patent, col. 20:20-25 The patent was issued January 2, 2018 Compl. ¶36

Asserted Claims

The complaint asserts infringement of "one or more claims" and specifically recites independent claim 1 Compl. ¶91 Compl. ¶93

Accused Features

The complaint alleges that Amneal's ANDA Product is a sterile liquid pharmaceutical solution containing phenylephrine, ketorolac, and a buffer system, stored in a single-use container, which infringes the claims of the '246 Patent Compl. ¶39 Compl. ¶¶94-96

III. The Accused Instrumentality

Product Identification

The accused instrumentality is Defendant Amneal's generic drug product described in Abbreviated New Drug Application (ANDA) No. 220463 (the "ANDA Product") Compl. ¶1

Functionality and Market Context

• The complaint alleges that the ANDA Product is a generic version of Rayner's OMIDRIA® (phenylephrine and ketorolac injection, 1%/0.3%) Compl. ¶1 It is described as a "sterile liquid pharmaceutical formulation stored in a single use container for addition to ocular irrigating solutions used during cataract surgery or intraocular lens replacement" Compl. ¶39 The act of infringement under 35 U.S.C. § 271(e)(2) is the submission of the ANDA itself to seek FDA approval for commercial manufacture, use, or sale before the expiration of the patents-in-suit Compl. ¶1
• The complaint alleges that Amneal intends to commercially manufacture, market, and sell the ANDA Product throughout the United States, which will displace sales of OMIDRIA® Compl. ¶12 Compl. ¶22

No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint does not provide specific, unredacted claim charts mapping elements to the accused product. The infringement theory appears to rely on the argument that, to gain FDA approval, a generic product must generally contain the same active and inactive ingredients in the same concentration as the reference listed drug, OMIDRIA®, which is covered by the patents-in-suit Compl. ¶48 Compl. ¶70 Compl. ¶92 The specific allegations of how the ANDA Product meets each claim limitation are contained in redacted paragraphs.

'856 Patent Infringement Allegations

'406 Patent Infringement Allegations

Identified Points of Contention

• Scope Questions: A primary point of contention for the '856 Patent may be the scope of the phrase "consisting essentially of." The infringement analysis may turn on whether any unlisted ingredients in Amneal's formulation materially alter the "basic and novel properties" of the claimed invention, namely its stability without conventional preservatives. For the '406 Patent, which uses the broader term "comprising," the focus may shift to the negative limitation "without the inclusion of preservatives and antioxidants" and whether any component in the ANDA product could be characterized as such.
• Technical Questions: A key evidentiary question will be the precise composition and stability data of Amneal's ANDA Product. While the complaint relies on regulatory requirements for sameness, discovery will be needed to confirm whether the accused formulation literally meets each claim limitation. The redaction of the complaint's specific infringement allegations Compl. ¶¶50-53 Compl. ¶¶72-74 suggests that the exact basis for these allegations is not yet public, raising the question of what evidence Plaintiff possesses regarding the formulation's specific characteristics.

V. Key Claim Terms for Construction

Term: "consisting essentially of" ('856 Patent, claim 1)

Context and Importance

This transitional phrase is critical for defining the scope of infringement. Its construction will determine whether Amneal's ANDA Product can avoid infringement by including ingredients not explicitly recited in the claim. The central question will be whether any such additional ingredients "materially affect the basic and novel properties" of the claimed stable, preservative-free solution.

Intrinsic Evidence for Interpretation

• Evidence for a Broader Interpretation: A party may argue that the "basic and novel properties" are simply stability and suitability for injection, and that only an unlisted ingredient that undermines these properties would be a material alteration. The specification focuses on achieving stability without traditional, toxic additives, which could support an interpretation that only such additives are material.
• Evidence for a Narrower Interpretation: A party may point to language emphasizing a "very pure formulation" '856 Patent, col. 9:48-49 and statements that preferred formulations "consist essentially of the two APIs and the buffering system in water for injection" '856 Patent, col. 9:45-48 This could support an argument that the inventors intended to exclude nearly all other excipients, making even minor, non-toxic additions "material."

Term: "without the inclusion of preservatives and antioxidants" ('406 Patent, claim 2)

Context and Importance

The construction of this negative limitation is central to the infringement analysis for the '406 Patent. The dispute will likely focus on whether any component in the ANDA Product, even if it has a different primary purpose, also functions as a "preservative" or "antioxidant" as those terms are used in the patent.

Intrinsic Evidence for Interpretation

• Evidence for a Broader Interpretation (i.e., more things are excluded): The specification provides a list of common preservatives and antioxidants that the invention sought to avoid '406 Patent, col. 7:31-45 A party may argue that this list is exemplary, not exhaustive, and that any substance with known antioxidant or preservative properties is excluded.
• Evidence for a Narrower Interpretation (i.e., fewer things are excluded): The patent explicitly allows for a citrate buffer, and the specification acknowledges that the citric acid component "provides an antioxidant effect as well as a buffering effect" but is not precluded '406 Patent, col. 9:30-38 This language may support an argument that a substance is not a prohibited "antioxidant" if its antioxidant properties are incidental to its primary, permissible function within the formulation, such as buffering.

VI. Other Allegations

Indirect Infringement

The complaint alleges induced infringement on the basis that Amneal, upon receiving FDA approval, will market and distribute its ANDA Product with a product insert and prescribing information that will allegedly instruct and encourage healthcare professionals to use the product in an infringing manner Compl. ¶55 Compl. ¶77 Compl. ¶99

Willful Infringement

The complaint alleges that Amneal had actual and constructive notice of the patents-in-suit prior to filing its ANDA Compl. ¶56 Compl. ¶78 Compl. ¶100 The filing of a Paragraph IV certification itself serves as evidence of knowledge. The complaint further alleges that Amneal's certification was made "without adequate justification," laying the groundwork for a claim that the case is "exceptional" and warrants an award of attorneys' fees under 35 U.S.C. § 285 Compl. ¶57 Compl. ¶79 Compl. ¶101

VII. Analyst's Conclusion: Key Questions for the Case

1. Definitional Scope vs. Formulation Chemistry: The case will likely hinge on questions of claim construction. For the '856 Patent, can the phrase "consisting essentially of" be interpreted to permit additional, unrecited excipients in the accused product without avoiding infringement? For the '406 and '246 Patents, does any component of Amneal's formulation function as a "preservative" or "antioxidant," even if incidentally, thereby falling afoul of the claims' negative limitations?

2. The Role of Regulatory Equivalence: A central pillar of the infringement allegation is the regulatory requirement for a generic drug to be the "same as" its branded counterpart. A key question will be how the court weighs this regulatory assumption against the specific chemical and stability data for Amneal's product that will emerge during discovery. A finding that the ANDA product is different enough to not infringe could raise questions about its approvability as a generic.

3. Objective Baselessness and Willfulness: The complaint repeatedly characterizes Amneal's ANDA filing as being "without adequate justification." This suggests a core issue will be the objective strength of Amneal's non-infringement and/or invalidity arguments. The development of this issue will determine whether Plaintiffs can successfully argue that the case is "exceptional" and pursue enhanced damages or attorneys' fees.